Targeted Cancer Therapeutics and Heart Failure: Mechanisms and Post-injury Repair

靶向癌症治疗和心力衰竭：机制和损伤后修复

• 批准号: 8150072
• 负责人: Thomas Force
• 金额: $ 37.8万
• 依托单位: THOMAS JEFFERSON UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2010
• 资助国家: 美国
• 起止时间: 2010-04-01 至 2013-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8150072
• 关键词: ABL1 gene; Accounting; Antineoplastic Agents; Apoptosis; Automobile Driving; Biology; Cardiac; Cardiac Myocytes; Cardiotoxicity; Cells; Chimeric Proteins; Clinical; Clinical Trials; Collaborations; Dasatinib; Data; Drops; Drug Design; EFRAC; Early identification; Early treatment; Evaluation; Exhibits; Fibrinogen; Future; Gleevec; Heart; Heart failure; Imatinib; Injury; Interruption; Lead; Left Ventricular Dysfunction; Left Ventricular Ejection Fraction; Left Ventricular Function; Life; Maintenance; Malignant Neoplasms; Measures; Mediating; Muscle Cells; Mutate; New Agents; Oncogenic; Pathway interactions; Patients; Pharmaceutical Preparations; Phosphotransferases; Play; Population; Process; Proliferating; Prospective Studies; Protein Tyrosine Kinase; Proto-Oncogene Protein c-kit; Recruitment Activity; Reliance; Reporting; Resistance; Risk; Severities; Side; Signal Pathway; Stem cells; Symptoms; Therapeutic; Toxic effect; Tyrosine Kinase Inhibitor; Withdrawal; Work; base; c-abl Proto-Oncogenes; cancer cell; cell killing; cost; design; functional decline; heart function; high risk; in vivo; inhibitor/antagonist; injury and repair; insight; mouse model; mutant; neoplastic cell; novel; prevent; prospective; repaired; restoration; small molecule; stem; stem cell biology; therapeutic target; vigilance